Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $11.80.

A number of brokerages recently issued reports on CMPX. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Monday, November 11th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, September 16th. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. D. Boral Capital assumed coverage on Compass Therapeutics in a research report on Monday, December 23rd. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $5.00 to $4.00 in a research note on Friday, November 15th.

Compass Therapeutics Trading Down 3.9 %

Shares of NASDAQ CMPX opened at $1.46 on Monday. The firm has a market cap of $200.88 million, a P/E ratio of -3.95 and a beta of 0.89. The business’s 50 day moving average is $1.60 and its 200-day moving average is $1.42. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Analysts forecast that Compass Therapeutics will post -0.35 EPS for the current year.

Institutional Trading of Compass Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after buying an additional 112,614 shares during the period. Geode Capital Management LLC increased its stake in shares of Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after acquiring an additional 19,095 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics in the 3rd quarter valued at $37,000. The Manufacturers Life Insurance Company acquired a new position in shares of Compass Therapeutics during the 3rd quarter valued at $79,000. Finally, Intech Investment Management LLC bought a new position in Compass Therapeutics during the third quarter worth $30,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.